Scoping review of apixaban and rivaroxaban dosing for atrial fibrillation and venous thromboembolism in advanced chronic kidney disease
This review summarizes apixaban and rivaroxaban dosing for AF/VTE in advanced CKD, revealing gaps such as limited dose-comparison studies, heterogeneous outcomes and sparse data in non-dialysis. Robust trials are urgently needed.
Authors
- Jennifer Pitman (ORCID: https://orcid.org/0000-0002-7250-1600)
- Louise Gillis (ORCID: https://orcid.org/0000-0001-8250-5886)
- Chiranjeev Sanyal (ORCID: https://orcid.org/0000-0003-3677-8036)
- Emma Phelan
- J. Asteph Wilson
- Shanna Trenaman (ORCID: https://orcid.org/0000-0002-7982-4437)
- Christopher Daley (ORCID: https://orcid.org/0000-0002-9002-5011)
- Stacy Gillis
- Marisa Battistella
- Karthik Tennankore
Institutions
- Dalhousie University (CA)
- Capital District Health Authority (CA)
- University Health Network (CA)
- Kellogg's (Canada) (CA)
- Nova Scotia Health Authority (CA)
Publication Details
- Journal
- International Journal of Clinical Pharmacy
- Published
- 2026-02-24
- DOI
- https://doi.org/10.1007/s11096-026-02096-1
- Primary Topic
- Atrial Fibrillation Management and Outcomes
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bayer Canada